BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  A Win for AI: FDA Approves BioXCel Therapy for Bipolar Disorder and Schizophrenia

  The U.S. Food and Drug Administration (FDA) has approved BioXcel Therapeutics’ Igalmi, a drug designed to reduce agitation episodes in bipolar disorder and schizophrenia patients.

  April 6, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano, M.S.
• 

  Drug Development

  Novartis Augments Transformational Week with US Approval, European Milestones

  With the accelerated approval from the U.S. Food and Drug Administration, Vijoice becomes the first treatment approved in the United States for PROS

  April 6, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  Global Roundup: Ginkgo/Microba Autoimmune Pact and New Parkinson’s Data

  Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.

  April 6, 2022

   · 

  7 min read

   · 

  Alex Keown
• 

  New Genomics Technology Could Power Gene Therapy in Oncology

  A team of scientists from Mount Sinai was able to uncover specific tumor microenvironment (TME) regulators using a novel functional genomics technology known as Perturb-map.

  April 6, 2022

   · 

  7 min read

   · 

  Abbey Glasure
• 

  Business

  Mysterious Retro Biosciences Launches to “Increase Healthy Human Lifespan by 10 Years”

  Retro Biosciences announced on Twitter that it is launching with $180 million in funding. Not much is known about the company, except that it indicates it is focused on the “cellular drives of aging.”

  April 6, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Leen Kawas Business Partner Stirs Up More Drama at Athira

  Athira Pharma is circling the wagons and urging shareholders to reject investor Richard Kayne’s calls for a management change.

  April 6, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  Esteemed Harvard Researcher Heads to Vertex to Curate Diabetes Portfolio

  Noted Harvard researcher Doug Melton is heading to Vertex Pharmaceuticals to head up investigations into potential transformative treatments for type 1 diabetes.

  April 6, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Boehringer Ingelheim Addresses Ukraine Crisis while Projecting 15 Launches by 2025

  Boehringer Ingelheim made a splash on Tuesday, announcing its intention to pump €25 billion ($27 billion) into its R&D pipeline over the next five years.

  April 6, 2022

   · 

  3 min read

   · 

  Heather McKenzie
• 

  Biotech Bay

  FDA Fully Revokes Authorization of GSK and Vir’s Sotrovimab for COVID-19

  The FDA has stated that GSK and Vir’s COVID-19 treatment sotrovimab is no longer authorized to be used for the condition because of its low efficacy against Omicron sub-variant BA.2.

  April 6, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Armed with Robust Data, Citius Will Seek Approval in T-cell lymphoma

  Citius Pharmaceuticals has shared positive topline data from its Phase III clinical trial of I/Ontak. The company plans to file a biologics license application with the FDA later this year.

  April 6, 2022

   · 

  2 min read

   · 

  Hayley Shasteen